Catabasis is a venture-funded, clinical stage company leveraging its proprietary SMART (Safely Metabolized And Targeted) linker technology to develop a robust pipeline of products targeting inflammatory, immunological and metabolic diseases. The SMART linker platform technology produces new chemical entities (NCEs) that have amplified efficacy along a clinically validated disease pathway through the conjugation of two known products via a linker that is metabolized intracellularly in cells relevant to the particular disease.
Catabasis was founded in 2008 by industry veterans Chief Executive Officer Jill Milne, Ph.D., Chief Scientific Officer Mike Jirousek, Ph.D., and Steven Shoelson, M.D., Ph.D., Harvard Medical School and Joslin Diabetes Center, on an approach that focuses on targeting inflammation to treat complex human diseases. In 2010, Catabasis closed a $48 million Series A financing. The company is backed by top-tier investors, including SV Life Sciences, Clarus Ventures, MedImmune Ventures and Advanced Technology Ventures.